Skip to main content
Log in

Comparison of Pharmacological Potency and Safety of Glutamate Blocker IEM-1913 and Memantine

  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

Adamantane-containing glutamate blocker IEM-1913 (1-amino-4-(1-adamantane-amino)-butane dihydrochloride) equals to memantine in antiparkinsonian potency, but surpasses it in anticonvulsive, antidepressant, and analgesic activities. Moreover, its use is less toxic and safer. IEM-1913 produces significant pharmacological effects at a wide concentration diapason (0.03-1.00 mg/kg), while memantine is effective within a narrow range only (15-20 mg/kg). High pharmacological efficacy and low toxicity of IEM-1913 can be explained by the fact that in contrast to monocationic selective NMDA antagonist memantine, the dicationic glutamate blocker IEM-1913 produces a combined block of cerebral NMDA and AMPA receptors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. S. I. Gavrilova, Ya. B. Kalyn, N. D. Selezneva, et al., Psikhiatr. Psikhofarmakoter., 7, No. 2, 72-76 (2005).

    Google Scholar 

  2. V. E. Gmiro and S. E. Serdyuk, Eksp. Klin. Farmakol., 63, No. 6, 3-8 (2000).

    CAS  PubMed  Google Scholar 

  3. V. E. Gmiro, A. V. Zhuravskii, I. V. Komissarov, and V. N. Tikhonov, Eksp. Klin. Farmakol., 65, No. 1, 11-14 (2002).

    CAS  PubMed  Google Scholar 

  4. V. E. Gmiro and S. E. Serdyuk, Bull. Exp. Biol. Med., 145, No. 6, 728-730 (2008).

    Article  CAS  PubMed  Google Scholar 

  5. S. E. Serdyuk and V. E. Gmiro, Bull. Exp. Biol. Med., 144, No. 5, 692-694 (2007).

    Article  CAS  PubMed  Google Scholar 

  6. W. Danysz, C. G. Parsons, J. Kornhuber, et al., Neurosci. Biobehav. Rev., 21, No. 4, 455-468 (1997).

    Article  CAS  PubMed  Google Scholar 

  7. C. Ikonomidou, V. Stefovska, and L. Turski, Proc. Natl Acad. Sci. USA, 97, No. 23, 12885-12890 (2000).

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. S. E. Krahl, S. S. Senanayake, and A. Handforth, Epilepsy Res., 38, Nos. 2-3, 171-175 (2000).

    Article  CAS  PubMed  Google Scholar 

  9. G. C. Palmer, Curr. Drug Targets, 2, No. 3, 241-271 (2001).

    Article  CAS  PubMed  Google Scholar 

  10. C. G. Parsons, G. Quack, I. Bresink, et al., Neuropharmacology, 34, No. 10, 1239-1258 (1995).

    Article  CAS  PubMed  Google Scholar 

  11. G. Rammes, W. Danysz, and C. G. Parsons, Curr. Neuropharmacol., 6, No. 1, 55-78 (2008).

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. M. Rogers, A. Rasheed, A. Moradimehr, and S. J. Baumrucker, Am. J. Hosp. Palliat. Care, 26, No. 1, 57-59 (2009).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to V. E. Gmiro.

Additional information

Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 160, No. 7, pp. 80-83, July, 2015

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gmiro, V.E., Serdyuk, S.E. & Veselkina, O.S. Comparison of Pharmacological Potency and Safety of Glutamate Blocker IEM-1913 and Memantine. Bull Exp Biol Med 160, 68–71 (2015). https://doi.org/10.1007/s10517-015-3100-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10517-015-3100-9

Key Words

Navigation